Table 3. Crude cancer incidence rates in patients and in the general population of French women (by decreasing order of SIR).
Patients | General population | ||||
---|---|---|---|---|---|
Second malignancy | Crude incidence rates 100 000 PY | SIR | 95% CI | P | |
Leukaemia | 30.4 | 8.7 | 2.07 | 1.52–2.75 | <0.0001 |
Ovarian | 47.6 | 14.9 | 1.6 | 1.27–2.04 | <0.0001 |
Gynaecological | 86.0 | 28.0 | 1.6 | 1.34–1.89 | <0.0001 |
Lung | 37.5 | 15.2 | 1.2 | 0.91–1.55 | 0.16 |
Malignant melanoma | 23.9 | 13.8 | 1.07 | 0.76–1.48 | 0.67 |
Lymphoma | 26.9 | 16.6 | 0.95 | 0.68–1.29 | 0.76 |
Genitourinary | 26.6 | 15.8 | 0.89 | 0.64–1.20 | 0.44 |
Thyroid | 12.9 | 9.6 | 0.87 | 0.53–1.35 | 0.54 |
Gastrointestinal | 119.1 | 15.9 | 0.82 | 0.70–0.95 | 0.007 |
Head and neck | 11.6 | 9.1 | 0.64 | 0.38–1.01 | 0.06 |
Sarcoma | 22.3 | NAa | — | — | — |
Abbreviations: CI=confidence interval; PY=person-years; SIR=standardized incidence ratio.
NA, not available by age for the general population of French women.